Palvella Therapeutics Inc
PVLA103.370USD
-2.460-2.32%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.15BMarket Cap
LossP/E TTM
More Details of Palvella Therapeutics Inc Company
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Palvella Therapeutics Inc Info
Ticker SymbolPVLA
Company namePalvella Therapeutics Inc
IPO dateDec 18, 2014
CEOKaupinen (Wesley H)
Number of employees14
Security typeOrdinary Share
Fiscal year-endDec 18
Address353 W. Lancaster Avenue
CityWAYNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19087
Phone14842531461
Websitehttps://palvellatx.com/
Ticker SymbolPVLA
IPO dateDec 18, 2014
CEOKaupinen (Wesley H)
Company Executives of Palvella Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Mr. Tadd S. Wessel
Mr. Tadd S. Wessel
Independent Director
Independent Director
--
--
Dr. David W. Osborne, Ph.D.
Dr. David W. Osborne, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
--
--
Dr. Jeffrey (Jeff) Martini, Ph.D.
Dr. Jeffrey (Jeff) Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Kaupinen (Wesley H.)
13.58%
BVF Partners L.P.
9.81%
Suvretta Capital Management, LLC
6.95%
Frazier Life Sciences Management, L.P.
6.10%
Integrated Finance Group
4.73%
Other
58.83%
Shareholders
Shareholders
Proportion
Kaupinen (Wesley H.)
13.58%
BVF Partners L.P.
9.81%
Suvretta Capital Management, LLC
6.95%
Frazier Life Sciences Management, L.P.
6.10%
Integrated Finance Group
4.73%
Other
58.83%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.48%
Investment Advisor/Hedge Fund
17.41%
Individual Investor
16.63%
Investment Advisor
13.20%
Private Equity
9.44%
Other Insider Investor
4.73%
Research Firm
2.39%
Venture Capital
1.87%
Bank and Trust
0.07%
Other
4.78%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
145
6.92M
62.61%
+1.10M
2025Q2
113
8.02M
72.53%
+1.47M
2025Q1
119
7.23M
65.51%
+2.66M
2024Q4
118
6.14M
54.71%
+5.00M
2024Q3
118
806.99K
64.03%
-218.37K
2024Q2
120
474.51K
38.85%
-479.71K
2024Q1
135
564.53K
48.12%
-430.81K
2023Q4
149
574.40K
48.95%
-409.12K
2023Q3
161
703.90K
61.81%
-282.90K
2023Q2
173
831.24K
82.60%
-68.86K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Kaupinen (Wesley H.)
1.61M
14.53%
--
--
Apr 14, 2025
BVF Partners L.P.
696.55K
6.3%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
714.46K
6.46%
--
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
722.40K
6.53%
+32.39K
+4.69%
Jun 30, 2025
Integrated Finance Group
559.95K
5.06%
+559.95K
--
Apr 14, 2025
The Vanguard Group, Inc.
163.81K
1.48%
+25.38K
+18.33%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
409.73K
3.7%
+298.98K
+269.95%
Jun 30, 2025
Woodline Partners LP
445.62K
4.03%
+251.45K
+129.50%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco Dorsey Wright SmallCap Momentum ETF
0.51%
ALPS Medical Breakthroughs ETF
0.37%
iShares Micro-Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
iShares Russell 2000 Growth ETF
0.03%
Global X Russell 2000 ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
View more
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.51%
ALPS Medical Breakthroughs ETF
Proportion0.37%
iShares Micro-Cap ETF
Proportion0.11%
Vanguard US Momentum Factor ETF
Proportion0.1%
iShares Russell 2000 Growth ETF
Proportion0.03%
Global X Russell 2000 ETF
Proportion0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Date
Type
Ratio
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
FAQs
Who are the top five shareholders of Palvella Therapeutics Inc?
The top five shareholders of Palvella Therapeutics Inc are:
Kaupinen (Wesley H.) holds 1.61M shares, accounting for 14.53% of the total shares.
BVF Partners L.P. holds 696.55K shares, accounting for 6.30% of the total shares.
Suvretta Capital Management, LLC holds 714.46K shares, accounting for 6.46% of the total shares.
Frazier Life Sciences Management, L.P. holds 722.40K shares, accounting for 6.53% of the total shares.
Integrated Finance Group holds 559.95K shares, accounting for 5.06% of the total shares.
Kaupinen (Wesley H.) holds 1.61M shares, accounting for 14.53% of the total shares.
BVF Partners L.P. holds 696.55K shares, accounting for 6.30% of the total shares.
Suvretta Capital Management, LLC holds 714.46K shares, accounting for 6.46% of the total shares.
Frazier Life Sciences Management, L.P. holds 722.40K shares, accounting for 6.53% of the total shares.
Integrated Finance Group holds 559.95K shares, accounting for 5.06% of the total shares.
What are the top three shareholder types of Palvella Therapeutics Inc?
The top three shareholder types of Palvella Therapeutics Inc are:
Kaupinen (Wesley H.)
BVF Partners L.P.
Suvretta Capital Management, LLC
Kaupinen (Wesley H.)
BVF Partners L.P.
Suvretta Capital Management, LLC
How many institutions hold shares of Palvella Therapeutics Inc (PVLA)?
As of 2025Q3, 145 institutions hold shares of Palvella Therapeutics Inc, with a combined market value of approximately 6.92M, accounting for 62.61% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.92%.
What is the biggest source of revenue for Palvella Therapeutics Inc?
In --, the -- business generated the highest revenue for Palvella Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
